Clinical trial
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid…
NCT00121264 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00121264 |
|---|---|
| Title | 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors |
| Official title | A Phase I Dose-Escalation Study of Intravenous 17-Allylaminogeldanamycin (17-AAG) [NSC 330507and Oral BAY 43-9006 [NSC 724772] Administered in Patients With Pretreated Advanced Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other, Procedure |
| Interventions | sorafenib tosylate, tanespimycin, laboratory biomarker analysis, pharmacological study, magnetic resonance imaging |
| Enrollment | 54 |
| Start date | Mar 1, 2005 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Jul 21, 2005 |
| Last update posted | Jun 17, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: